Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Femasys Inc. Market Cap
The Femasys Inc. (FEMY) share price is expected to increase by 636.61% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered FEMY. Price targets range from $3 at the low end to $12 at the high end. The current analyst consensus for FEMY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
FEMY is a stock in Healthcare which has been forecasted to be worth $8.25 as an average. On the higher end, the forecast price is $12 USD by Keay Nakae from Chardan Capital and on the lower end FEMY is forecasted to be $3 by from .
These are the latest 20 analyst ratings of FEMY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Dec 3, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Nov 27, 2024 |
| Keay Nakae Chardan Capital | Buy | $8 | Maintains | Nov 13, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Nov 12, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Oct 31, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Reiterates | Sep 12, 2024 |
| Keay Nakae Chardan Capital | Buy | $10 | Maintains | Aug 14, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Maintains | Aug 9, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $13 | Reiterates | Jun 20, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $13 | Reiterates | May 9, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $12 | Maintains | Apr 1, 2024 |
| Keay Nakae Chardan Capital | Buy | $12 | Maintains | Apr 1, 2024 |
| Keay Nakae Chardan Capital | Buy | $12 | Reiterates | Mar 21, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $10 | Reiterates | Mar 21, 2024 |
| Catherine Novack JonesTrading | Buy | $10 | Maintains | Mar 20, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $10 | Maintains | Nov 14, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $13 | Maintains | Sep 29, 2023 |
| Lina Kaminski JonesTrading | Buy | $7 | Maintains | Sep 26, 2023 |
| Keay Nakae Chardan Capital | Buy | $10 | Reiterates | Aug 11, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $5 | Reiterates | Aug 10, 2023 |
When did it IPO
2021
Staff Count
32
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Ms. Kathy Lee-Sepsick M.B.A.
Market Cap
$24.7M
In 2023, FEMY generated $1.1M in revenue, which was a decrease of -11.13% from the previous year. This can be seen as a signal that FEMY's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Trial results for FemaSeed intratubal insemination show it is safe and effective, with high satisfaction from both practitioners and patients.
Why It Matters - Positive trial results for FemaSeed intratubal insemination indicate potential market growth and increased demand, which could boost stock value for related healthcare companies.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company has accelerated its commercialization efforts through new partnerships in both the U.S. and Europe.
Why It Matters - New partnerships in the U.S. and Europe indicate strong growth potential and market expansion, which can enhance revenue and boost investor confidence in the company's future performance.
Tue, 12 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Femasys Inc. (FEMY) reported a quarterly loss of $0.24 per share, worse than the expected loss of $0.20, but an improvement from a loss of $0.26 per share a year earlier.
Why It Matters - Femasys Inc.'s larger-than-expected quarterly loss may signal operational challenges, potentially affecting investor confidence and stock performance. Year-over-year improvement is noted, but not enough to meet estimates.
Fri, 01 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Femasys has secured a new patent for FemBloc, enhancing its coverage for a permanent birth control option aimed at women.
Why It Matters - FemBloc's patent enhances Femasys' market position in women's healthcare, potentially increasing revenue and attracting investor interest in the growing reproductive health sector.
Thu, 10 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The VP of Education and Global Training at the company has been appointed Chairman of the ASRM Corporate Member Council.
Why It Matters - Leadership changes can impact a company's strategic direction and industry relationships, potentially influencing its market position and long-term growth prospects.
Wed, 02 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Femasys, Inc. (Nasdaq: FEMY) received its second order from strategic partners following successful FemaSeed® procedures in Europe. The treatment targets infertility by delivering sperm directly into the fallopian tube.
Why It Matters - Femasys's successful commercial launch and second order for FemaSeed in Europe signal growing demand for innovative infertility treatments, potentially boosting revenue and market position.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
